Page results
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
UCLH has declared a climate and health emergency and has published an action plan to reach net zero carbon dioxide emissions.
-
North Mid, UCLH and Whittington Health are running a fun, uplifting, informative event for people with sickle cell on Saturday 25th June 2022.
-
Our staff have rated UCLH as the top trust in London to work at, and the third best in the country, during what has been another incredibly challenging year.
-
The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
Having proton beam therapy under general anaesthetic: information for children aged 5-8 patient information
-
Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information.
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
Having originally studied classics, and having first worked in publishing and in the British Library, I became a lawyer and spent ten years in commercial litigation practice in the City.
File results
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0244 - IT systems for digital dictation, speech recognition, outsourced transcription, video consultation and health information systems
-
FOI/2023/0247 - Treatment guidelines for Idiopathic Pulmonary Fibrosis
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0360 - Minutes of Board of Director meetings and Declarations of Interests (DoI) statements 2008-2023